NCT01173731
Who may be able to join
Who might be able to join this trial:
- You have Parkinson's disease and are being treated with a medication called L-Dopa
- You experience involuntary movements (called dyskinesias) as a result of your Parkinson's treatment
- You are an outpatient (meaning you are not staying in a hospital)
- You previously took part in and successfully completed a related earlier study involving a drug called AFQ056
Who may not be able to join:
- You have had surgery to treat your Parkinson's disease
- You have been diagnosed with cancer in the last 5 years (except for certain skin cancers or prostate cancer that has already been successfully treated)
- You have another serious or unstable health condition (not Parkinson's disease) that could affect the results of the study
- There may be additional requirements not listed here that the trial team will check (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence and severity of AEs/SAEs, changes in vital signs, lab assessments and ECGs, in cognitive function (MMSE), psychiatric symptoms (SCOPA-PC), and underlying symptoms of PD (UPDRS part III, CGIC, PGIC).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.